Dr. Tarantino on the Impact of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

Video

Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.

Paolo Tarantino, MD, researcher, the European Institute of Oncology, clinical research fellow, Dana-Farber Cancer Institute, discusses the impact of the phase 3 DESTINY-Breast04 trial (NCT03734029) in the treatment of HER2-low breast cancer.

The study compared fam-trastuzumab deruxtecan-nxki (Enhertu) to a physician’s choice of chemotherapy in patients with HER2-low breast cancer that has been previously treated.

This trial affected treatment decisions for patients with HER2-low breast cancer, who represent a sizeable portion of the breast cancer population, Tarantino says. Data from DESTINY-Breast04 presented at the 2022 ASCO Annual Meeting demonstrated a benefit in overall response rate, progression-free survival, and overall survival for trastuzumab deruxtecan compared with chemotherapy.

Despite the advances made in HER2-low breast cancer, questions remain in this field, including if trastuzumab deruxtecan can elicit a benefit in patients with HER2-zero breast cancer, Tarantino explains. The phase 3 DESTINY-Breast06 trial (NCT04494425) will help investigators answer more questions about the utility of trastuzumab deruxtecan, Tarantino concludes.

Related Videos
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD
Kohei Shitara, MD
Shruti Tiwari, MD